Skip to content

Neuro-feedback Therapy for Treating Tinnitus

Neuro-feedback Therapy for Treating Tinnitus : Efficacy Pilot Study on a Targeted Population

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03773926
Acronym
TNTA
Enrollment
30
Registered
2018-12-12
Start date
2018-05-28
Completion date
2019-01-15
Last updated
2018-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearing Loss, Tinnitus

Keywords

Tinnitus, Neuro-feedback, Male, Female, Tinnitus Handicap Inventory

Brief summary

Neuro-feedback for treating tinnitus seem to be a promising approach to help people suffering from chronic tinnitus. The past studies on this approach suffered interindividual variability in their results. The investigators' current hypothesis is that the variability of the results is the consequences of two possible flaws: lack of appropriate patient selection and lack of support of the patient during the therapy. This study is aimed at testing these hypotheses.

Detailed description

Many individuals with tinnitus have abnormal oscillatory brain activity in their temporal areas (Weisz et al. (2005), Schlee et al. (2014)). Led by this finding, attempts to normalize such localized pathological activity by neuro-feedback techniques have been tested (Dohrmann et al. (2007), Gütenspenger et al. (2017)). These attempts highlighted interindividual variability that can be explained by lack of selection of the patient population and lack of guidance through the therapy. The present study is aimed at addressing these issues by choosing more selectively a patient subpopulation (tinnitus associated with moderate hearing loss) and by implementing a guidance interface during the treatment. The therapy will consist of 10 neuro-feedback training sessions of 29 minutes over 5 weeks. Each session will be composed of 6 blocks of 3 min in which the patient will be incited to practise a specific cognitive strategy (mental exercise such as think to a music you like) and resting state measurements. Each patient who has been recruited to fit our inclusion and non-inclusion criteria will first go through a clinical assessment of his initial judgment criteria metrics. Then subjects will go through the 5-week training and then will be evaluated on the same criteria just after the end of the therapy and at 3 months after the end of it.

Interventions

DEVICENeuro-feedback therapy

The therapy consists of 10 Neuro-feedback training sessions, 2 times per week over 5 weeks.

Sponsors

University Hospital, Toulouse
CollaboratorOTHER
Zeta Technologies
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

An efficiency multicentric pilot study on a targeted population for development and use of Neuro-feedback therapy for treating tinnitus.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

: * Age \> 18 * Social security affiliation * Permanent, non-fluctuation, high pitch, bilateral or assimilated, tinnitus * Mean value of the VAS at least at 6 between the intensity and the disturbance criteria at the recruitment interview. * THI score superior or equal to 40 at the recruitment interview * Written consent to the protocol * Associated hearing-loss characterized by : * mean value of the hearing threshold loss for the 250, 500 and 1000 Hz thresholds strictly under 25 dB (deciBel). * at least one hearing threshold among the 2000, 4000, 6000 and 8000 Hz with at least 30 dB of hearing loss. * mean value of the hearing threshold loss for the 2000, 4000, 6000 and 8000 Hz thresholds strictly under 70 dB.

Exclusion criteria

* Subjects under legal protection (guardianship, trusteeship or judicial protection) * Notable cognitive disability impeding to understanding or performing the cognitive tasks * Meniere's disease, chronic or serous otitis, acoustic neuroma * Pulsatile tinnitus, somatosensorial tinnitus * Epilepsy * No antidepressant or anti-epileptic drug treatment * DET (DETresse) questionnaire (measure of tinnitus associated distress) above or equal to 40 * Use of a sound generator during the therapy * Pregnancy or breastfeeding * Inability to wear the electrodes headset of the neuro-feedback device

Design outcomes

Primary

MeasureTime frameDescription
Comparison of initial and final Tinnitus Handicap Inventory (THI) distributionsComparison of initial and final THI before and after treatment for a Time frame of 5 weeks.This primary outcome measure denotes the evolution of the deterioration of the quality of life of patients due to tinnitus. THI is a questionnaire composed of 25 questions each with 3 response options converting in 0, 2, and 4 points scoring, making it a scale from 0 to 100 points.

Secondary

MeasureTime frameDescription
Evolution of Tinnitus Handicap Inventory (THI) and Visual Analog Scales (VAS) on tinnitus intensity and associated disturbance 3 month after the treatment3 months after the end of the 5 week treatmentEvaluation of maintenance of effects perceived 3 months after the treatment. The THI and the VAS scales are used similarly to the precedent outcome measures. THI is a questionnaire composed of 25 questions each with 3 response options converting in 0, 2, and 4 points scoring, making it a scale from 0 to 100 points. the Visual Analog Scale (VAS) for intensity of Tinnitus enables the patient to rate his tinnitus intensity with integers values between 1 to 10 (included). The Visual Analog Scale (VAS) for Tinnitus associated disturbance enables the patient to rate his tinnitus associated diturbance with integers values between 1 to 10 (included). For both visual analog scales, a high value (near 10) indicates a high gravity of the symptom, regarding either its intensity or its associated disturbance, while low values (near 1), indicate lighter impact of the symptom regarding its intensity or its associated disturbance.
Side effectsThe total duration of the studyEvaluation of potential side effects during the study. At each session patients will be asked if they want to declare any side effects they believe to be related to the treatment.
Comparison of initial and final Visual Analog Scale (VAS) distributionsComparison of initial and final VAS before and after treatment for a Time frame of 5 weeks.The secondary outcome measure denotes the evolution of the intensity of tinnitus and the disturbance associated measured by two scales. First the Visual Analog Scale (VAS) for intensity of Tinnitus enables the patient to rate his tinnitus intensity with integers values between 1 to 10 (included). Second, the Visual Analog Scale (VAS) for Tinnitus associated disturbance enables the patient to rate his tinnitus associated diturbance with integers values between 1 to 10 (included). For both scales, a high value (near 10) indicates a high gravity of the symptom, regarding either its intensity or its associated disturbance, while low values (near 1), indicate lighter impact of the symptom regarding its intensity or its associated disturbance. The scores are assessed subjectively by the patient when asked.
Correlation of the electrophysiological measurements and the THI/VAS measurementsOver the 5 weeks of treatmentCorrelation between the plastic effects induced by therapy on electrophysiological measurements and the assessment of the severity of tinnitus through the THI/VAS.
Evolution of the THI, BAHIA, and VAS scores, expressed as a percentage of the initial valueComparison of initial and final measurements before and after treatment for a Time frame of 5 weeks.Evolution of the precedent quoted measures before and after treatment measured as percentages of the initial value (proportion of evolution of the THI, VAS and BAHIA measurements).
Evolution of pathological attention level (BAHIA) standing for (in french) Biphasique, Acouphène, Hyperacousie, Insensibilité de la face et Autres sensations.Comparison of initial and final BAHIA before and after treatment for a Time frame of 5 weeks.Evaluation of the proportion of daily time that the patient reports experiencing and being disturbed by his tinnitus through 4 questions.

Countries

France

Contacts

Primary ContactAlain LONDERO
Alain.londero@aphp.fr05 61 77 21 19
Backup ContactRenaud SIMEON
r.simeon@ch-bry.org01 40 19 36 61

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026